MedTrace Logo

Cardiac Troponin Fragmentation After Heavy Physical Exercise The MaraCat2 Study

NCT06000930 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2024-05-08

No results posted yet for this study

Summary

Cardiac troponins are highly sensitive and specific biomarkers of cardiac injury and are in a key role in the diagnosis of acute myocardial infarction (MI). Minor troponin elevations are common after prolonged strenuous exercise without clinical symptoms of MI or myocardial injury. Importantly, currently used high-sensitivity troponin T (cTnT) test detects also smaller troponin fragments which may cause troponin elevation after exercise and lead to false diagnosis of MI.

In the present study protocol, we compare the characteristics troponin release after marathon race and Type 1 MI with the improved version of our novel troponin fragmentation test (SuperTropo test) and the commercial cTnT test.

A total of 65 recreational runners participating in the 2023 Paavo Nurmi Marathon in Turku are recruited. All participants give a blood sample during the post-race visit (within 30 min after finishing the marathon).

A control group of 90 patients with acute Type 1 MI are recruited among patients admitted to Heart Centre of Turku University Hospital.

Commercial cTnT and long troponin component of cTnT analyzed witha novel immunoassay are dtermined in all subjects to assess cTnT fragmentation. TYhe main aims of the study are:

To assess how often cTnT is elevated after marathon running and which factors affect the cTnT rise? Is the fragmentation of troponin more common after marathon race compared with Type 1 MI and can the novel Supertropo test separate execise-induced troponin rise from those caused by MI ?

Conditions

Interventions

DIAGNOSTIC_TEST

Troponin fragmentation

laboratory test from blood sample

Sponsors & Collaborators

  • Turku University Hospital

    collaborator OTHER_GOV

  • University of Turku

    lead OTHER

Principal Investigators

  • Juhani K Airaksinen, Md, PhD · Turku University Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-19
Primary Completion
2024-09-01
Completion
2024-09-01

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06000930 on ClinicalTrials.gov